Rivastigmine Capsules in Patients With Probable Vascular Dementia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT00130338
First received: August 11, 2005
Last updated: November 16, 2011
Last verified: November 2011

August 11, 2005
November 16, 2011
February 2002
May 2006   (final data collection date for primary outcome measure)
Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaD
Not Provided
Complete list of historical versions of study NCT00130338 on ClinicalTrials.gov Archive Site
52 week's treatment with rivastigmine on cognition, activities of daily living, behavior and clinical staging in patients with VaD and probable VaD
Not Provided
Not Provided
Not Provided
 
Rivastigmine Capsules in Patients With Probable Vascular Dementia
An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Vascular Dementia
Drug: Rivastigmine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
521
May 2006
May 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who complete the double-blind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved drop-out patients) without significant protocol violations are eligible to participate.

Exclusion Criteria:

  • Retrieved drop-out patients, who have been treated with other cholinergic drugs during the past 4 weeks
Both
50 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00130338
CENA713BIA05E1
Not Provided
Novartis
Novartis
Not Provided
Not Provided
Novartis
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP